View ValuationLaboratorios RichmondC.I.F 将来の成長Future 基準チェック /06現在、 Laboratorios RichmondC.I.Fの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Pharmaceuticals 収益成長13.5%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesNew Risk • May 28New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 13% Last year net profit margin: 21% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (1.6x net interest cover). Minor Risks Paying a dividend despite having no free cash flows. Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (13% net profit margin). Market cap is less than US$100m (AR$132.0b market cap, or US$93.6m).Declared Dividend • May 13Dividend reduced to AR$16.10Dividend of AR$16.10 is 40% lower than last year. Ex-date: 14th May 2026 Payment date: 15th May 2026 Dividend yield will be 1.0%, which is lower than the industry average of 2.4%. Sustainability & Growth Dividend is being paid despite the company being loss-making over the last 12 months and having no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The dividend has increased by an average of 117% per year over the past 5 years. However, payments have been volatile during that time.お知らせ • May 13Laboratorios Richmond S.A.C.I.F. announces Annual dividend, payable on May 15, 2026Laboratorios Richmond S.A.C.I.F. announced Annual dividend of ARS 16.0988 per share payable on May 15, 2026, ex-date on May 14, 2026 and record date on May 14, 2026.お知らせ • Mar 30Laboratorios Richmond S.A.C.I.F., Annual General Meeting, Apr 30, 2026Laboratorios Richmond S.A.C.I.F., Annual General Meeting, Apr 30, 2026. Location: held remotely, ArgentinaNew Risk • Feb 26New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: AR$132.4b (US$94.2m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (2.7% operating cash flow to total debt). Dividend is not well covered by earnings and cash flows. Paying a dividend despite being loss-making. Paying a dividend despite having no free cash flows. Minor Risk Market cap is less than US$100m (AR$132.4b market cap, or US$94.2m).New Risk • Feb 11New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Argentinean stocks, typically moving 7.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Debt is not well covered by operating cash flow (2.7% operating cash flow to total debt). Minor Risk Share price has been volatile over the past 3 months (7.2% average weekly change).Reported Earnings • Nov 10Third quarter 2025 earnings released: AR$114 loss per share (vs AR$68.76 profit in 3Q 2024)Third quarter 2025 results: AR$114 loss per share (down from AR$68.76 profit in 3Q 2024). Revenue: AR$30.9b (up 57% from 3Q 2024). Net loss: AR$9.17b (down 265% from profit in 3Q 2024). Over the last 3 years on average, earnings per share has increased by 49% per year but the company’s share price has increased by 68% per year, which means it is tracking significantly ahead of earnings growth.Valuation Update With 7 Day Price Move • Oct 27Investor sentiment improves as stock rises 24%After last week's 24% share price gain to AR$1,395, the stock trades at a trailing P/E ratio of 9.8x. Average trailing P/E is 25x in the Pharmaceuticals industry globally. Total returns to shareholders of 313% over the past three years.Reported Earnings • Aug 11Second quarter 2025 earnings released: AR$34.82 loss per share (vs AR$53.34 profit in 2Q 2024)Second quarter 2025 results: AR$34.82 loss per share (down from AR$53.34 profit in 2Q 2024). Revenue: AR$25.2b (up 19% from 2Q 2024). Net loss: AR$2.81b (down 165% from profit in 2Q 2024). Over the last 3 years on average, earnings per share has increased by 55% per year but the company’s share price has increased by 72% per year, which means it is tracking significantly ahead of earnings growth.New Risk • May 16New minor risk - Dividend sustainabilityThe company has an unstable dividend paying track record. The dividend has had an annual drop of over 20% in the past. Dividend yield: 1.8% This is considered a minor risk. If the company has cut or reduced its dividend in the past, it may be a sign that the underlying business is too cyclical to consistently maintain or grow the dividend over the long-term. It may also indicate the company prioritizes other outcomes instead of maintaining the dividend. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Major Risk Debt is not well covered by operating cash flow (3.9% operating cash flow to total debt). Minor Risk Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past.お知らせ • May 09Laboratorios Richmond S.A.C.I.F. announces Annual dividend, payable on May 15, 2025Laboratorios Richmond S.A.C.I.F. announced Annual dividend of ARS 26.8897 per share payable on May 15, 2025, ex-date on May 14, 2025 and record date on May 14, 2025.New Risk • Apr 14New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: AR$113.1b (US$95.0m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Debt is not well covered by operating cash flow (3.9% operating cash flow to total debt). Minor Risk Market cap is less than US$100m (AR$113.1b market cap, or US$95.0m).Valuation Update With 7 Day Price Move • Apr 08Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to AR$1,405, the stock trades at a trailing P/E ratio of 4.8x. Average trailing P/E is 21x in the Pharmaceuticals industry globally. Total returns to shareholders of 503% over the past three years.お知らせ • Mar 21Laboratorios Richmond S.A.C.I.F., Annual General Meeting, Apr 29, 2025Laboratorios Richmond S.A.C.I.F., Annual General Meeting, Apr 29, 2025. Location: held remotely via zoom, ArgentinaReported Earnings • Mar 10Full year 2024 earnings releasedFull year 2024 results: Revenue: AR$91.8b (up 135% from FY 2023). Net income: AR$23.8b (up AR$34.7b from FY 2023). Profit margin: 26% (up from net loss in FY 2023). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has increased by 91% per year, which means it is tracking significantly ahead of earnings growth.Reported Earnings • Nov 10Third quarter 2024 earnings released: EPS: AR$68.76 (vs AR$25.31 loss in 3Q 2023)Third quarter 2024 results: EPS: AR$68.76 (up from AR$25.31 loss in 3Q 2023). Revenue: AR$19.7b (up 252% from 3Q 2023). Net income: AR$5.55b (up AR$7.60b from 3Q 2023). Profit margin: 28% (up from net loss in 3Q 2023). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has increased by 101% per year, which means it is tracking significantly ahead of earnings growth.Valuation Update With 7 Day Price Move • Oct 24Investor sentiment improves as stock rises 26%After last week's 26% share price gain to AR$1,205, the stock trades at a trailing P/E ratio of 27.4x. Average trailing P/E is 18x in the Pharmaceuticals industry in South America. Total returns to shareholders of 405% over the past three years.Reported Earnings • Aug 18Second quarter 2024 earnings released: EPS: AR$36.64 (vs AR$15.93 loss in 2Q 2023)Second quarter 2024 results: EPS: AR$36.64 (up from AR$15.93 loss in 2Q 2023). Revenue: AR$17.0b (up 112% from 2Q 2023). Net income: AR$2.96b (up AR$4.24b from 2Q 2023). Profit margin: 17% (up from net loss in 2Q 2023). The move to profitability was driven by higher revenue. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 144 percentage points per year, which is a significant difference in performance.New Risk • Nov 25New major risk - Revenue and earnings growthEarnings have declined by 8.8% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (0.2x net interest cover). Earnings have declined by 8.8% per year over the past 5 years.Reported Earnings • Mar 15Full year 2022 earnings releasedFull year 2022 results: Revenue: AR$18.5b (up 11% from FY 2021). Net income: AR$163.4m (down 72% from FY 2021). Profit margin: 0.9% (down from 3.6% in FY 2021). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 64% per year whereas the company’s share price has increased by 60% per year.Board Change • Nov 16Less than half of directors are independentThere are 6 new directors who have joined the board in the last 3 years. Of these new board members, 1 was an independent director. The company's board is composed of: 2 independent directors. 7 non-independent directors. Independent Director Daniel Razetto was the last independent director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity.Valuation Update With 7 Day Price Move • Oct 04Investor sentiment improved over the past weekAfter last week's 15% share price gain to AR$340, the stock trades at a trailing P/E ratio of 20.1x. Average trailing P/E is 18x in the Pharmaceuticals industry in South America. Total returns to shareholders of 452% over the past three years.Board Change • Apr 27No independent directorsThere is 1 new director who has joined the board in the last 3 years. The new board member was not an independent director. The company's board is composed of: 1 new director. 11 experienced directors. No highly experienced directors. No independent directors (7 non-independent directors). Chairman of Supervisory Committee Santiago Lizzoli was the last director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.Valuation Update With 7 Day Price Move • Apr 21Investor sentiment improved over the past weekAfter last week's 49% share price gain to AR$259, the stock trades at a trailing P/E ratio of 58.6x. Average trailing P/E is 23x in the Pharmaceuticals industry globally. Total returns to shareholders of 699% over the past three years.Valuation Update With 7 Day Price Move • Feb 27Investor sentiment improved over the past weekAfter last week's 21% share price gain to AR$184, the stock is trading at a trailing P/E ratio of 41.6x, up from the previous P/E ratio of 34.5x. This compares to an average P/E of 24x in the Pharmaceuticals industry. Total returns to shareholders over the past three years are 533%.Is New 90 Day High Low • Feb 12New 90-day high: AR$150The company is up 36% from its price of AR$110 on 13 November 2020. The Argentinean market is up 1.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 13% over the same period.Valuation Update With 7 Day Price Move • Feb 10Investor sentiment improved over the past weekAfter last week's 17% share price gain to AR$139, the stock is trading at a trailing P/E ratio of 31.5x, up from the previous P/E ratio of 27x. This compares to an average P/E of 24x in the Pharmaceuticals industry. Total returns to shareholders over the past three years are 381%.Is New 90 Day High Low • Jan 27New 90-day high: AR$123The company is up 19% from its price of AR$104 on 28 October 2020. The Argentinean market is flat over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 13% over the same period.Is New 90 Day High Low • Dec 16New 90-day high: AR$123The company is up 18% from its price of AR$104 on 16 September 2020. The Argentinean market is up 24% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is up 6.0% over the same period.Is New 90 Day High Low • Nov 27New 90-day high: AR$115The company is up 7.0% from its price of AR$107 on 28 August 2020. The Argentinean market is up 20% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is down 6.0% over the same period. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Laboratorios RichmondC.I.F は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測BASE:RICH - アナリストの将来予測と過去の財務データ ( )ARS Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数3/31/2026119,64216,051-31,724-1,988N/A12/31/2025126,7262,404-52,4631,866N/A9/30/2025139,6413,355-36,97814,115N/A6/30/2025134,73419,842-27,49915,690N/A3/31/2025132,81827,512-22,51015,901N/A12/31/2024120,75431,368-4,1927,396N/A9/30/2024101,87510,110-12,3066,246N/A6/30/202493,235-3,522-22,306-493N/A3/31/202487,983-12,605-30,230-4,772N/A12/31/202384,989-23,629-31,800-4,544N/A9/30/202387,633-11,207-42,706-14,832N/A6/30/202376,914-5,305-40,380-14,105N/A3/31/202372,109286-33,534-11,009N/A12/31/202257,518509-36,761-13,346N/A9/30/202245,7783,055-25,282-3,980N/A6/30/202248,2793,327-12,8884,316N/A3/31/202236,2241,899-12,0993,999N/A12/31/202132,3661,152-4,2747,274N/A9/30/202119,7272905142,981N/A6/30/202112,651635-3,159-431N/A3/31/202110,091584-978199N/A12/31/20209,330734-1,099-181N/A9/30/20207,680486-942-541N/A6/30/20206,97831968445N/A3/31/20206,140235-50453N/A12/31/20195,303159N/A121N/A9/30/20193,902-84N/A-26N/A6/30/20193,343-284N/A-63N/A3/31/20193,013-414N/A-96N/A12/31/20182,795-332N/A-182N/A9/30/20182,820-306N/A-138N/A6/30/20182,296-125N/A-228N/A3/31/20181,90413N/A-257N/A12/31/20171,59149N/A11N/A9/30/20171,048100N/A79N/A6/30/2017988103N/A100N/A3/31/2017912106N/A63N/A12/31/201685695N/A-4N/A9/30/201665328N/A-48N/A6/30/201656814N/A-11N/A3/31/201650412N/A-19N/A12/31/20154466N/A-25N/A9/30/201540717N/A5N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: RICHの予測収益成長が 貯蓄率 ( 8.9% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: RICHの収益がAR市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: RICHの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: RICHの収益がAR市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: RICHの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: RICHの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/07/01 22:00終値2026/07/01 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Laboratorios Richmond S.A.C.I.F. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
New Risk • May 28New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 13% Last year net profit margin: 21% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (1.6x net interest cover). Minor Risks Paying a dividend despite having no free cash flows. Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (13% net profit margin). Market cap is less than US$100m (AR$132.0b market cap, or US$93.6m).
Declared Dividend • May 13Dividend reduced to AR$16.10Dividend of AR$16.10 is 40% lower than last year. Ex-date: 14th May 2026 Payment date: 15th May 2026 Dividend yield will be 1.0%, which is lower than the industry average of 2.4%. Sustainability & Growth Dividend is being paid despite the company being loss-making over the last 12 months and having no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The dividend has increased by an average of 117% per year over the past 5 years. However, payments have been volatile during that time.
お知らせ • May 13Laboratorios Richmond S.A.C.I.F. announces Annual dividend, payable on May 15, 2026Laboratorios Richmond S.A.C.I.F. announced Annual dividend of ARS 16.0988 per share payable on May 15, 2026, ex-date on May 14, 2026 and record date on May 14, 2026.
お知らせ • Mar 30Laboratorios Richmond S.A.C.I.F., Annual General Meeting, Apr 30, 2026Laboratorios Richmond S.A.C.I.F., Annual General Meeting, Apr 30, 2026. Location: held remotely, Argentina
New Risk • Feb 26New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: AR$132.4b (US$94.2m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (2.7% operating cash flow to total debt). Dividend is not well covered by earnings and cash flows. Paying a dividend despite being loss-making. Paying a dividend despite having no free cash flows. Minor Risk Market cap is less than US$100m (AR$132.4b market cap, or US$94.2m).
New Risk • Feb 11New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Argentinean stocks, typically moving 7.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Debt is not well covered by operating cash flow (2.7% operating cash flow to total debt). Minor Risk Share price has been volatile over the past 3 months (7.2% average weekly change).
Reported Earnings • Nov 10Third quarter 2025 earnings released: AR$114 loss per share (vs AR$68.76 profit in 3Q 2024)Third quarter 2025 results: AR$114 loss per share (down from AR$68.76 profit in 3Q 2024). Revenue: AR$30.9b (up 57% from 3Q 2024). Net loss: AR$9.17b (down 265% from profit in 3Q 2024). Over the last 3 years on average, earnings per share has increased by 49% per year but the company’s share price has increased by 68% per year, which means it is tracking significantly ahead of earnings growth.
Valuation Update With 7 Day Price Move • Oct 27Investor sentiment improves as stock rises 24%After last week's 24% share price gain to AR$1,395, the stock trades at a trailing P/E ratio of 9.8x. Average trailing P/E is 25x in the Pharmaceuticals industry globally. Total returns to shareholders of 313% over the past three years.
Reported Earnings • Aug 11Second quarter 2025 earnings released: AR$34.82 loss per share (vs AR$53.34 profit in 2Q 2024)Second quarter 2025 results: AR$34.82 loss per share (down from AR$53.34 profit in 2Q 2024). Revenue: AR$25.2b (up 19% from 2Q 2024). Net loss: AR$2.81b (down 165% from profit in 2Q 2024). Over the last 3 years on average, earnings per share has increased by 55% per year but the company’s share price has increased by 72% per year, which means it is tracking significantly ahead of earnings growth.
New Risk • May 16New minor risk - Dividend sustainabilityThe company has an unstable dividend paying track record. The dividend has had an annual drop of over 20% in the past. Dividend yield: 1.8% This is considered a minor risk. If the company has cut or reduced its dividend in the past, it may be a sign that the underlying business is too cyclical to consistently maintain or grow the dividend over the long-term. It may also indicate the company prioritizes other outcomes instead of maintaining the dividend. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Major Risk Debt is not well covered by operating cash flow (3.9% operating cash flow to total debt). Minor Risk Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past.
お知らせ • May 09Laboratorios Richmond S.A.C.I.F. announces Annual dividend, payable on May 15, 2025Laboratorios Richmond S.A.C.I.F. announced Annual dividend of ARS 26.8897 per share payable on May 15, 2025, ex-date on May 14, 2025 and record date on May 14, 2025.
New Risk • Apr 14New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: AR$113.1b (US$95.0m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Debt is not well covered by operating cash flow (3.9% operating cash flow to total debt). Minor Risk Market cap is less than US$100m (AR$113.1b market cap, or US$95.0m).
Valuation Update With 7 Day Price Move • Apr 08Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to AR$1,405, the stock trades at a trailing P/E ratio of 4.8x. Average trailing P/E is 21x in the Pharmaceuticals industry globally. Total returns to shareholders of 503% over the past three years.
お知らせ • Mar 21Laboratorios Richmond S.A.C.I.F., Annual General Meeting, Apr 29, 2025Laboratorios Richmond S.A.C.I.F., Annual General Meeting, Apr 29, 2025. Location: held remotely via zoom, Argentina
Reported Earnings • Mar 10Full year 2024 earnings releasedFull year 2024 results: Revenue: AR$91.8b (up 135% from FY 2023). Net income: AR$23.8b (up AR$34.7b from FY 2023). Profit margin: 26% (up from net loss in FY 2023). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has increased by 91% per year, which means it is tracking significantly ahead of earnings growth.
Reported Earnings • Nov 10Third quarter 2024 earnings released: EPS: AR$68.76 (vs AR$25.31 loss in 3Q 2023)Third quarter 2024 results: EPS: AR$68.76 (up from AR$25.31 loss in 3Q 2023). Revenue: AR$19.7b (up 252% from 3Q 2023). Net income: AR$5.55b (up AR$7.60b from 3Q 2023). Profit margin: 28% (up from net loss in 3Q 2023). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has increased by 101% per year, which means it is tracking significantly ahead of earnings growth.
Valuation Update With 7 Day Price Move • Oct 24Investor sentiment improves as stock rises 26%After last week's 26% share price gain to AR$1,205, the stock trades at a trailing P/E ratio of 27.4x. Average trailing P/E is 18x in the Pharmaceuticals industry in South America. Total returns to shareholders of 405% over the past three years.
Reported Earnings • Aug 18Second quarter 2024 earnings released: EPS: AR$36.64 (vs AR$15.93 loss in 2Q 2023)Second quarter 2024 results: EPS: AR$36.64 (up from AR$15.93 loss in 2Q 2023). Revenue: AR$17.0b (up 112% from 2Q 2023). Net income: AR$2.96b (up AR$4.24b from 2Q 2023). Profit margin: 17% (up from net loss in 2Q 2023). The move to profitability was driven by higher revenue. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 144 percentage points per year, which is a significant difference in performance.
New Risk • Nov 25New major risk - Revenue and earnings growthEarnings have declined by 8.8% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (0.2x net interest cover). Earnings have declined by 8.8% per year over the past 5 years.
Reported Earnings • Mar 15Full year 2022 earnings releasedFull year 2022 results: Revenue: AR$18.5b (up 11% from FY 2021). Net income: AR$163.4m (down 72% from FY 2021). Profit margin: 0.9% (down from 3.6% in FY 2021). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 64% per year whereas the company’s share price has increased by 60% per year.
Board Change • Nov 16Less than half of directors are independentThere are 6 new directors who have joined the board in the last 3 years. Of these new board members, 1 was an independent director. The company's board is composed of: 2 independent directors. 7 non-independent directors. Independent Director Daniel Razetto was the last independent director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity.
Valuation Update With 7 Day Price Move • Oct 04Investor sentiment improved over the past weekAfter last week's 15% share price gain to AR$340, the stock trades at a trailing P/E ratio of 20.1x. Average trailing P/E is 18x in the Pharmaceuticals industry in South America. Total returns to shareholders of 452% over the past three years.
Board Change • Apr 27No independent directorsThere is 1 new director who has joined the board in the last 3 years. The new board member was not an independent director. The company's board is composed of: 1 new director. 11 experienced directors. No highly experienced directors. No independent directors (7 non-independent directors). Chairman of Supervisory Committee Santiago Lizzoli was the last director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
Valuation Update With 7 Day Price Move • Apr 21Investor sentiment improved over the past weekAfter last week's 49% share price gain to AR$259, the stock trades at a trailing P/E ratio of 58.6x. Average trailing P/E is 23x in the Pharmaceuticals industry globally. Total returns to shareholders of 699% over the past three years.
Valuation Update With 7 Day Price Move • Feb 27Investor sentiment improved over the past weekAfter last week's 21% share price gain to AR$184, the stock is trading at a trailing P/E ratio of 41.6x, up from the previous P/E ratio of 34.5x. This compares to an average P/E of 24x in the Pharmaceuticals industry. Total returns to shareholders over the past three years are 533%.
Is New 90 Day High Low • Feb 12New 90-day high: AR$150The company is up 36% from its price of AR$110 on 13 November 2020. The Argentinean market is up 1.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 13% over the same period.
Valuation Update With 7 Day Price Move • Feb 10Investor sentiment improved over the past weekAfter last week's 17% share price gain to AR$139, the stock is trading at a trailing P/E ratio of 31.5x, up from the previous P/E ratio of 27x. This compares to an average P/E of 24x in the Pharmaceuticals industry. Total returns to shareholders over the past three years are 381%.
Is New 90 Day High Low • Jan 27New 90-day high: AR$123The company is up 19% from its price of AR$104 on 28 October 2020. The Argentinean market is flat over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 13% over the same period.
Is New 90 Day High Low • Dec 16New 90-day high: AR$123The company is up 18% from its price of AR$104 on 16 September 2020. The Argentinean market is up 24% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is up 6.0% over the same period.
Is New 90 Day High Low • Nov 27New 90-day high: AR$115The company is up 7.0% from its price of AR$107 on 28 August 2020. The Argentinean market is up 20% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is down 6.0% over the same period.